TEVA PHARMACEUTICAL-SP ADR reported Q1 adjusted EPS of $0.53, beating LSEG analyst estimates of $0.48 on Wednesday midday. The results for the Israel-based firm were driven by strong demand for its branded medicine portfolio. Investors are monitoring Teva's shift toward high-margin branded drugs to offset pricing pressures in its core generics business.
Teva's $0.53 adjusted profit per share represents a 10.4% beat against market expectations. LSEG data confirmed the outperformance during the Wednesday morning session.











